Clinical Trials Logo
  1. Home
  2. Other
  3. NCT01628107

A Phase 3, Long-Term Safety Study of Intravenous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin — AiME - 03  

Chronic Renal Failure Requiring Hemodialysis Clinical Trial

Official title:
A Phase III, Open-label, Multicenter, Long-term Safety Study Of Intravenous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment

Clinical Trial Summary

The purpose of the study is to determine the long-term safety in treatment-emergent adverse events (TEAEs) of intravenous (IV) administration of Epoetin Hospira for maintenance of target hemoglobin (Hgb) levels in patients treated for anemia associated with chronic renal failure and on hemodialysis.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01628107
Study type Interventional
Source Pfizer
Contact
Status Completed
Phase Phase 3
Start date July 16, 2012
Completion date January 2, 2015
View Details
See also
  Status Clinical Trial Phase
Completed NCT01628120 - A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin Phase 3
Terminated NCT02794142 - Oxidative Stress on Muscle Dysfunction in Hemodialysis Patient N/A